Sarepta Therapeutics, Inc. (SRPT) News

Sarepta Therapeutics, Inc. (SRPT): $117.12

0.16 (+0.14%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add SRPT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#59 of 359

in industry

Filter SRPT News Items

SRPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SRPT News Highlights

  • For SRPT, its 30 day story count is now at 15.
  • Over the past 22 days, the trend for SRPT's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • AGE, DNLI and EAR are the most mentioned tickers in articles about SRPT.

Latest SRPT News From Around the Web

Below are the latest news stories about SAREPTA THERAPEUTICS INC that investors may wish to consider to help them evaluate SRPT as an investment opportunity.

3 Things About Sarepta Therapeutics Every Smart Investor Knows

Mastering this stock requires appreciating a few scientific nuances.

Yahoo | December 28, 2023

15 Best Fast Growth Stocks to Buy Now

In this article, we will take a look at the 15 best fast growth stocks to buy now. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Best Fast Growth Stocks to Buy Now. Vanguard Growth ETF is one of the most famous growth focused […]

Yahoo | December 27, 2023

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […]

Yahoo | December 26, 2023

Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day

Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.

Yahoo | December 26, 2023

Sarepta Therapeutics Seen Expanding Duchenne Treatment Label

Sarepta Therapeutics may be on the cusp of expanding the label for its Duchenne Muscular Dystrophy treatment, according to Mizuho analyst Uy Ear. The company has submitted an efficacy supplement to the FDA for Elevidys, requesting expanded approval for all DMD patients. The treatment's current label restricts its use to 4- to 5-year-old ambulatory patients.

Yahoo | December 22, 2023

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Yahoo | December 22, 2023

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024

Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.

Yahoo | December 22, 2023

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

CAMBRIDGE, Mass., December 22, 2023--Sarepta submits efficacy supplement to expand ELEVIDYS label to include Duchenne patients without restriction to age or ambulatory status

Yahoo | December 22, 2023

Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval

The biotech is asking the agency to clear its treatment Elevidys in more patients with the disease, despite a confirmatory trial that missed its main goal.

Yahoo | December 22, 2023

An Intrinsic Calculation For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Suggests It's 42% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sarepta Therapeutics fair value estimate is US$155 Current...

Yahoo | December 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!